BSX · Boston Scientific Corporation
$45.69
-0.70% last session
End-of-day data · close of 2026-10-23
Market cap
$66B
Enterprise value
$79B
Trailing P/E
18.5
Forward P/E
13.5
Dividend yield
0.0%
Beta
0.57
Avg volume
20M
Employees
59K
Daily Change %
-0.70%
5 Days Change
3.65%
10 Days Change
6.23%
30 Days Change
3.12%
60 Days Change
-6.12%
Month to Day Change
6.43%
Year to Day Change
-51.75%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BSX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-14
Latest call per bank · past 12 months
Barclays
Equal-Weight$48.00
+5.1% vs priceCitigroup
Neutral$48.00
+5.1% vs priceWells Fargo
Equal-Weight$48.00
+5.1% vs priceUBS
Buy$67.00
+46.6% vs priceRBC Capital
Outperform$70.00
+53.2% vs priceJefferies
Buy$67.00
+46.6% vs priceBank of America
Buy$68.00
+48.8% vs priceGoldman Sachs
Buy$84.00
+83.8% vs priceJP Morgan
Overweight$100
+118.9% vs priceMorgan Stanley
Overweight$118
+158.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Truist Securities | Maintains | Buy | $57.00 → $51.00 |
| 2026-10-07 | Barclays | Initiates | Equal-Weight | $0.00 → $48.00 |
| 2026-10-05 | Citigroup | Maintains | Neutral | $50.00 → $48.00 |
| 2026-09-24 | Wells Fargo | Maintains | Equal-Weight | $50.00 → $48.00 |
| 2026-09-21 | Oppenheimer | Maintains | Outperform | $85.00 → $65.00 |
| 2026-09-17 | Citigroup | Downgrade | Buy → Neutral | $57.00 → $50.00 |
| 2026-09-09 | BTIG | Maintains | Buy | $60.00 → $56.00 |
| 2026-08-25 | TD Cowen | Reiterates | Buy | $56.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 0.3% above the 50-day MA ($45.54).
- bearish: Price vs 200-day MA: Trading 21.0% below the 200-day MA ($57.83).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.44) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($41.58).
BSX Price Chart
Loading chart for BSX…
Fundamentals
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
More in Medical Devices
ABT
Abbott Laboratories
$179B -16.2% YTD
MDT
Medtronic plc.
$122B 3.1% YTD
SYK
Stryker Corporation
$118B -11.9% YTD
EW
Edwards Lifesciences Corporatio
$51B 5.7% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.8% YTD
DXCM
DexCom, Inc.
$29B 18.0% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 3.3% YTD
STE
STERIS plc (Ireland)
$23B -7.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.